Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01422330 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients
A Phase 4 study, sponsored by Janssen R&D Ireland.
- Completed
- Registry status
- Phase 4
- Development phase
- 211
- Enrollment target
NCT01422330 is a Phase 4 study that has completed, run by Janssen R&D Ireland. The registered enrollment target is 211 participants.
The verdict
NCT01422330, a Phase 4 study, has completed, sponsored by Janssen R&D Ireland.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 211 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about the safety and tolerability of etravirine. Etravirine is a type of non-nucleoside reverse transcriptase inhibitor (NNRTI) which has shown high activity against wild-type human immunodeficiency virus (HIV-1), and HIV strains resistant to other non-nucleotide agents.
Interventions
- DRUG Etravirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01422330
The ClinicalTrials.gov registry entry for NCT01422330 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen R&D Ireland, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etravirine is the first listed.
NCT01422330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01422330 about?
NCT01422330 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients". The purpose of this study is to learn more about the safety and tolerability of etravirine. Etravirine is a type of non-nucleoside reverse transcriptase inhibitor (NNRTI) which has shown high activity against wild-type human immunodeficiency virus (HIV-1), and HIV strains resistant to other non-nucl...
What is the current status of trial NCT01422330?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 211 participants. The study started on 2011-09. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01422330?
The interventions under investigation include: Etravirine (DRUG).
Who is sponsoring clinical trial NCT01422330?
This trial is sponsored by Janssen R&D Ireland, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.